Compare MDGL & ONTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | ONTO |
|---|---|---|
| Founded | 2011 | 1940 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 6.6B |
| IPO Year | N/A | N/A |
| Metric | MDGL | ONTO |
|---|---|---|
| Price | $570.45 | $154.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $553.08 | $151.25 |
| AVG Volume (30 Days) | 313.6K | ★ 774.4K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.55 |
| Revenue | $740,640,000.00 | ★ $1,002,336,000.00 |
| Revenue This Year | $436.04 | $3.72 |
| Revenue Next Year | $53.17 | $17.19 |
| P/E Ratio | ★ N/A | $44.03 |
| Revenue Growth | ★ 864.21 | 6.38 |
| 52 Week Low | $265.00 | $85.88 |
| 52 Week High | $605.00 | $228.42 |
| Indicator | MDGL | ONTO |
|---|---|---|
| Relative Strength Index (RSI) | 59.89 | 58.74 |
| Support Level | $546.20 | $156.89 |
| Resistance Level | $589.67 | $171.32 |
| Average True Range (ATR) | 22.68 | 6.47 |
| MACD | -6.14 | 1.37 |
| Stochastic Oscillator | 45.10 | 65.34 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.